AB Science is currently conducting a Phase 3 clinical trial to evaluate the efficacy and safety of masitinib in combination with riluzole for the treatment of ALS. The market for ALS therapies is competitive, with riluzole being the current standard of care. If successful, masitinib could provide a novel therapeutic option that enhances the effects of riluzole, potentially capturing a significant share of the ALS treatment market. The trial is actively recruiting across multiple international sites, indicating robust interest and investment in this therapeutic area. The outcome of this trial could influence AB Science's market positioning and valuation significantly, especially if the results demonstrate a statistically significant improvement in ALSFRS-R scores compared to placebo.